HIF1A and COVID-19: These findings provide mechanistic insights into post-COVID-19 cognitive impairment and highlight the potential of metformin as a repurposed therapeutic agent capable of modulating key pathological cascades, including HIF-1α stabilization and protein aggregation, associated with long COVID (Fig 7).